Kenvue Aktie News

Kenvue Inc (NYSE:KVUE), the consumer health company spun off from Johnson & Johnson (NYSE:JNJ) in 2023, is considering selling a selection of its smaller skin health and beauty brands to streamline this segment and refocus on its core products, according to a Reuters report. The report, which cited four people with knowledge of the matter, is considering the sale of brands such as Clean & Clear...

Kenvue is exploring the sale of some of its skin health and beauty brands, four people familiar with the matter said on Thursday, as the consumer health firm prunes an underperforming business segment to focus on core products.

PHILADELPHIA, PA / ACCESS Newswire / June 9, 2025 / Kaskela Law LLC announces that it is investigating potential breach of fiduciary duty claims concerning Kenvue Inc. (NYSE:KVUE) on behalf of the company's long-term investors. Click here to receive additional information about your legal rights and options: https://kaskelalaw.com/case/kenvue/ Recently a securities fraud complaint was filed aga...

I initiate Kenvue with a 'Buy' rating and a $26 fair value, citing its iconic brands and steady dividend appeal. Kenvue's global operations, diversified product lines, and strong R&D enable resilience and ongoing margin expansion through cost efficiencies. Short-term headwinds from China destocking and tariffs are manageable, with long-term organic growth expected to normalize at 4.5%.

Most Dividend Kings are currently overpriced, but six offer fair value where annual dividends from $1,000 invested exceed their share price. Three top-yield Dividend Kings—Altria, Northwest Natural, and Canadian Utilities—meet the ideal 'dogcatcher' standard for fair pricing and dividend safety. Analyst projections suggest select Dividend Kings could deliver up to 58% total returns by June 2026...

Kenvue Chief Executive Thibaut Mongon said the consumer continues to be under pressure.

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for the first time since becoming a fully independent company. With 2024 full year sales of $15.5 billion, Kenvue is listed at number 281. The company's debut is a testament to the power of its iconic b...

Looking for high-yield dividend stocks below $50? Here are the top five.